{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T22:32:50Z","timestamp":1790548370290,"version":"4.1.0"},"reference-count":195,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDM"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec><jats:title>Abstract:<\/jats:title><jats:p>Huntington's disease (HD) is a distressing, innate neurodegenerative disease that descends from CAG repeat expansion in the huntingtin gene causing behavioral changes, motor dysfunction, and dementia in children and adults. Mutation in huntingtin (HTT) protein has been suggested to cause neuron loss in the cortex and striatum through various mechanisms, including abnormal regulation of transcription, proteasomal dysfunction, posttranslational modification, and other events regulating toxicity. Pathogenesis of HD involves cleavage of the huntingtin protein followed by the neuronal accumulation of its aggregated form. Several research groups made possible efforts to reduce huntingtin gene expression, protein accumulation, and protein aggregation using inhibitors and molecular chaperones as developing drugs against HD. Herein, we review the mechanism proposed towards the formation of HTT protein aggregation and the impact of therapeutic strategies for the treatment of HD.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1389200223666220321103942","type":"journal-article","created":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T20:01:56Z","timestamp":1647979316000},"page":"260-282","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A Review On Huntington Protein: Insight Into Protein Aggregation and Therapeutic Interventions"],"prefix":"10.2174","volume":"23","author":[{"given":"Ekambaram","family":"Srinivasan","sequence":"first","affiliation":[{"name":"Department of Bioinformatics, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences (SIMATS), Thandalam, Chennai - 602105, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vavish","family":"Ram","sequence":"additional","affiliation":[{"name":"Department of Bioinformatics, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences (SIMATS), Thandalam, Chennai - 602105, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramalingam","family":"Rajasekaran","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, School of Bio Sciences and Technology, Quantitative Biology Lab, Vellore Institute of Technology, Vellore - 632014, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1146\/annurev.neuro.23.1.217","volume":"23","author":"Zoghbi H.Y.","year":"2000","unstructured":"Zoghbi H.Y.; Orr H.T.; Glutamine repeats and neurodegeneration. Annu Rev Neurosci 2000,23(1),217-247","journal-title":"Annu Rev Neurosci"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/B978-0-12-385883-2.00010-2","volume":"107","author":"Zheng Z.","year":"2012","unstructured":"Zheng Z.; Diamond M.I.; Chapter 6 - Huntington Disease and the Huntingtin Protein Prog Mol Biol Transl Sci 2012,107,189-214","journal-title":"Prog Mol Biol Transl Sci"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/mds.25075","volume":"27","author":"Pringsheim T.","year":"2012","unstructured":"Pringsheim T.; Wiltshire K.; Day L.; Dykeman J.; Steeves T.; Jette N.; The incidence and prevalence of Huntington\u2019s disease: A system-atic review and meta-analysis. Mov Disord 2012,27(9),1083-1091","journal-title":"Mov Disord"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/35000576","volume":"403","author":"Smith M.A.","year":"2000","unstructured":"Smith M.A.; Brandt J.; Shadmehr R.; Motor disorder in Huntington\u2019s disease begins as a dysfunction in error feedback control. Nature 2000,403(6769),544-549","journal-title":"Nature"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1136\/jnnp.2006.103309","volume":"78","author":"Julien C.L.","year":"2007","unstructured":"Julien C.L.; Thompson J.C.; Wild S.; Yardumian P.; Snowden J.S.; Turner G.; Craufurd D.; Psychiatric disorders in preclinical Hunting-ton\u2019s disease. J Neurol Neurosurg Psychiatry 2007,78(9),939-943","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1007\/s11910-011-0215-x","volume":"11","author":"Paulsen J.S.","year":"2011","unstructured":"Paulsen J.S.; Cognitive impairment in Huntington disease: diagnosis and treatment. Curr Neurol Neurosci Rep 2011,11(5),474-483","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/B978-0-12-381328-2.00014-6","volume":"98","author":"Reiner A.","year":"2011","unstructured":"Reiner A.; Dragatsis I.; Dietrich P.; Genetics and neuropathology of Huntington\u2019s disease. Int Rev Neurobiol 2011,98,325-372","journal-title":"Int Rev Neurobiol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/B978-0-12-801942-9.00008-2","author":"Kim E.H.","year":"2017","unstructured":"Kim E.H.; Mehrabi N.; Tippett L.J.; Waldvogel H.J.; Faull R.L.M.; Cereb Cortex Neurodegener Neu-ropsychiatr Disord 2017,195-221","journal-title":"Cereb Cortex Neurodegener Neu-ropsychiatr Disord"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1021\/acs.biochem.6b00936","volume":"56","author":"Adegbuyiro A.","year":"2017","unstructured":"Adegbuyiro A.; Sedighi F.; Pilkington A.W.; Groover S.; Legleiter J.; Proteins containing expanded polyglutamine tracts and neuro-degenerative disease. Biochemistry 2017,56(9),1199-1217","journal-title":"Biochemistry"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1093\/hmg\/ddr023","volume":"20","author":"Havel L.S.","year":"2011","unstructured":"Havel L.S.; Wang C-E.; Wade B.; Huang B.; Li S.; Li X-J.; Preferential accumulation of N-terminal mutant Huntingtin in the nuclei of striatal neurons is regulated by phosphorylation. Hum Mol Genet 2011,20(7),1424-1437","journal-title":"Hum Mol Genet"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/aps.2018.11","volume":"39","author":"Harding R.J.","year":"2018","unstructured":"Harding R.J.; Tong Y.F.; Proteostasis in Huntington\u2019s disease: disease mechanisms and therapeutic opportunities. Acta Pharmacol Sin 2018,39(5),754-769","journal-title":"Acta Pharmacol Sin"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.nbd.2011.07.001","volume":"45","author":"Seredenina T.","year":"2012","unstructured":"Seredenina T.; Luthi-Carter R.; What have we learned from gene expression profiles in Huntington\u2019s disease? Neurobiol Dis 2012,45(1),83-98","journal-title":"Neurobiol Dis"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.freeradbiomed.2013.04.016","volume":"62","author":"Johri A.","year":"2013","unstructured":"Johri A.; Chandra A.; Flint Beal M.; PGC-1\u03b1 mitochondrial dysfunction, and Huntington\u2019s disease. Free Radic Biol Med 2013,62,37-46","journal-title":"Free Radic Biol Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.neuroscience.2012.05.043","volume":"251","author":"Nithianantharajah J.","year":"2013","unstructured":"Nithianantharajah J.; Hannan A.J.; Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington\u2019s disease. Neuroscience 2013,251,66-74","journal-title":"Neuroscience"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.1038\/cddis.2011.112","volume":"2","author":"Bano D.","year":"2011","unstructured":"Bano D.; Zanetti F.; Mende Y.; Nicotera P.; Neurodegenerative processes in Huntington\u2019s disease. Cell Death Dis 2011,2(11),e228-e228","journal-title":"Cell Death Dis"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1093\/hmg\/ddv080","volume":"24","author":"Mattis V.B.","year":"2015","unstructured":"Mattis V.B.; Tom C.; Akimov S.; Saeedian J.; \u00d8stergaard M.E.; Southwell A.L.; Doty C.N.; Ornelas L.; Sahabian A.; Lenaeus L.; Mandefro B.; Sareen D.; Arjomand J.; Hayden M.R.; Ross C.A.; Svendsen C.N.; HD iPSC-derived neural progenitors accumulate in cul-ture and are susceptible to BDNF withdrawal due to glutamate toxicity. Hum Mol Genet 2015,24(11),3257-3271","journal-title":"Hum Mol Genet"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1093\/nar\/gnf082","volume":"30","author":"M\u00f6ncke-Buchner E.","year":"2002","unstructured":"M\u00f6ncke-Buchner E.; Reich S.; M\u00fccke M.; Reuter M.; Messer W.; Wanker E.E.; Kr\u00fcger D.H.; Counting CAG repeats in the Huntington\u2019s disease gene by restriction endonuclease EcoP15I cleavage. Nucleic Acids Res 2002,30(16),e83","journal-title":"Nucleic Acids Res"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/ajmg.b.30992","volume":"153B","author":"Langbehn D.R.","year":"2010","unstructured":"Langbehn D.R.; Hayden M.R.; Paulsen J.S.; CAG-repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approaches. Am J Med Genet B Neuropsychiatr Genet 2010,153B(2),397-408","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/jmg.31.5.377","volume":"31","author":"Trottier Y.","year":"1994","unstructured":"Trottier Y.; Biancalana V.; Mandel J.L.; Instability of CAG repeats in Huntington\u2019s disease: Relation to parental transmission and age of onset. J Med Genet 1994,31(5),377-382","journal-title":"J Med Genet"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1136\/jmg.25.9.589","volume":"25","author":"Ridley R.M.","year":"1988","unstructured":"Ridley R.M.; Frith C.D.; Crow T.J.; Conneally P.M.; Anticipation in Huntington\u2019s disease is inherited through the male line but may origi-nate in the female. J Med Genet 1988,25(9),589-595","journal-title":"J Med Genet"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"19152","DOI":"10.1038\/s41598-019-55202-x","volume":"9","author":"Aviolat H.","year":"2019","unstructured":"Aviolat H.; Pinto R.M.; Godschall E.; Murtha R.; Richey H.E.; Sapp E.; Vodicka P.; Wheeler V.C.; Kegel-Gleason K.B.; DiFiglia M.; Assessing average somatic CAG repeat instability at the protein level. Sci Rep 2019,9(1),19152","journal-title":"Sci Rep"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1001\/jamaneurol.2019.2368","volume":"76","author":"Langbehn D.R.","year":"2019","unstructured":"Langbehn D.R.; Stout J.C.; Gregory S.; Mills J.A.; Durr A.; Leavitt B.R.; Roos R.A.C.; Long J.D.; Owen G.; Johnson H.J.; Borowsky B.; Craufurd D.; Reilmann R.; Landwehrmeyer G.B.; Scahill R.I.; Tabrizi S.J.; Association of CAG repeats with long-term progression in Huntington disease. JAMA Neurol 2019,76(11),1375-1385","journal-title":"JAMA Neurol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.3174\/ajnr.A6168","volume":"40","author":"Sampedro F.","year":"2019","unstructured":"Sampedro F.; Mart\u00ednez-Horta S.; Perez-Perez J.; Horta-Barba A.; Martin-Lahoz J.; Alonso-Sol\u00eds A.; Corripio I.; Gomez-Anson B.; Kulisevsky J.; Widespread increased diffusivity reveals early cortical degeneration in Huntington disease. Am J Neuroradiol 2019,40(9),1464-1468","journal-title":"Am J Neuroradiol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fmolb.2019.00020","volume":"6","author":"Shacham T.","year":"2019","unstructured":"Shacham T.; Sharma N.; Lederkremer G.Z.; Protein misfolding and ER stress in Huntington\u2019s disease. Front Mol Biosci 2019,6,20","journal-title":"Front Mol Biosci"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1021\/bi500300c","volume":"53","author":"Sahoo B.","year":"2014","unstructured":"Sahoo B.; Singer D.; Kodali R.; Zuchner T.; Wetzel R.; Aggregation behavior of chemically synthesized, full-length Huntingtin exon1. Biochemistry 2014,53(24),3897-3907","journal-title":"Biochemistry"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/jnc.14853","volume":"151","author":"Wanker E.E.","year":"2019","unstructured":"Wanker E.E.; Ast A.; Schindler F.; Trepte P.; Schnoegl S.; The pathobiology of perturbed mutant Huntingtin protein-protein interactions in Huntington\u2019s disease. J Neurochem 2019,151(4),507-519","journal-title":"J Neurochem"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.celrep.2015.08.060","volume":"13","author":"Huang S.","year":"2015","unstructured":"Huang S.; Yang S.; Guo J.; Yan S.; Gaertig M.A.; Li S.; Li X.J.; Large polyglutamine repeats cause muscle degeneration in SCA17 mice. Cell Rep 2015,13(1),196-208","journal-title":"Cell Rep"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"100056","DOI":"10.1016\/j.prdoa.2020.100056","volume":"3","author":"Gatto E.M.","year":"2020","unstructured":"Gatto E.M.; Rojas N.G.; Persi G.; Etcheverry J.L.; Cesarini M.E.; Perandones C.; Huntington disease: Advances in the understanding of its mechanisms. Clin Park Relat Disord 2020,3,100056","journal-title":"Clin Park Relat Disord"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"38183","DOI":"10.1074\/jbc.M110.160218","volume":"285","author":"Lotz G.P.","year":"2010","unstructured":"Lotz G.P.; Legleiter J.; Aron R.; Mitchell E.J.; Huang S-Y.; Ng C.; Glabe C.; Thompson L.M.; Muchowski P.J.; Hsp70 and Hsp40 func-tionally interact with soluble mutant Huntingtin oligomers in a classic ATP-dependent reaction cycle. J Biol Chem 2010,285(49),38183-38193","journal-title":"J Biol Chem"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3389\/fnins.2017.00185","volume":"11","author":"Ciechanover A.","year":"2017","unstructured":"Ciechanover A.; Kwon Y.T.; Protein quality control by molecular chaperones in neurodegeneration. Front Neurosci 2017,11,185","journal-title":"Front Neurosci"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-pathmechdis-012418-012857","volume":"14","author":"Lieberman A.P.","year":"2019","unstructured":"Lieberman A.P.; Shakkottai V.G.; Albin R.L.; Polyglutamine repeats in neurodegenerative diseases. Annu Rev Pathol 2019,14(1),1-27","journal-title":"Annu Rev Pathol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"837015","DOI":"10.1155\/2012\/837015","volume":"2012","author":"Schipper-Krom S.","year":"2012","unstructured":"Schipper-Krom S.; Juenemann K.; Reits E.A.J.; The ubiquitin-proteasome system in Huntington\u2019s disease: Are proteasomes impaired, initiators of disease, or coming to the rescue? Biochem Res Int 2012,2012,837015","journal-title":"Biochem Res Int"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3389\/fnmol.2014.00077","volume":"7","author":"Ortega Z.","year":"2014","unstructured":"Ortega Z.; Lucas J.J.; Ubiquitin-proteasome system involvement in Huntington\u2019s disease. Front Mol Neurosci 2014,7,77","journal-title":"Front Mol Neurosci"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1089\/ars.2012.4928","volume":"19","author":"Haun F.","year":"2013","unstructured":"Haun F.; Nakamura T.; Shiu A.D.; Cho D-H.; Tsunemi T.; Holland E.A.; La Spada A.R.; Lipton S.A.; S-nitrosylation of dynamin-related protein 1 mediates mutant Huntingtin-induced mitochondrial fragmentation and neuronal injury in Huntington\u2019s disease. Antioxid Redox Signal 2013,19(11),1173-1184","journal-title":"Antioxid Redox Signal"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"dmm031930","DOI":"10.1242\/dmm.031930","volume":"11","author":"Massey T.H.","year":"2018","unstructured":"Massey T.H.; Jones L.; The central role of DNA damage and repair in CAG repeat diseases. Dis Model Mech 2018,11(1),dmm031930","journal-title":"Dis Model Mech"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1016\/j.celrep.2019.02.008","volume":"26","author":"Ooi J.","year":"2019","unstructured":"Ooi J.; Langley S.R.; Xu X.; Utami K.H.; Sim B.; Huang Y.; Harmston N.P.; Tay Y.L.; Ziaei A.; Zeng R.; Low D.; Aminkeng F.; Sobota R.M.; Ginhoux F.; Petretto E.; Pouladi M.A.; Unbiased profiling of isogenic huntington disease hPSC-derived CNS and peripheral cells reveals strong cell-type specificity of CAG length effects. Cell Rep 2019,26(9),2494-2508.e7","journal-title":"Cell Rep"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"18696","DOI":"10.1038\/s41598-019-55177-9","volume":"9","author":"Gallardo-Orihuela A.","year":"2019","unstructured":"Gallardo-Orihuela A.; Herv\u00e1s-Corpi\u00f3n I.; Hierro-Bujalance C.; Sanchez-Sotano D.; Jim\u00e9nez-G\u00f3mez G.; Mora-L\u00f3pez F.; Campos-Caro A.; Garcia-Alloza M.; Valor L.M.; Transcriptional correlates of the pathological phenotype in a Huntington\u2019s disease mouse model. Sci Rep 2019,9(1),18696","journal-title":"Sci Rep"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"a024240","DOI":"10.1101\/cshperspect.a024240","volume":"7","author":"Jimenez-Sanchez M.","year":"2017","unstructured":"Jimenez-Sanchez M.; Licitra F.; Underwood B.R.; Rubinsztein D.C.; Huntington\u2019s Disease: Mechanisms of pathogenesis and therapeutic strategies. Cold Spring Harb Perspect Med 2017,7(7),a024240","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/sj.embor.7400250","volume":"5","author":"Landles C.","year":"2004","unstructured":"Landles C.; Bates G.P.; Huntingtin and the molecular pathogenesis of Huntington\u2019s disease. Fourth in molecular medicine review series. EMBO Rep 2004,5(10),958-963","journal-title":"EMBO Rep"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"89","DOI":"10.59566\/IJBS.2011.7089","volume":"7","author":"Sari Y.","year":"2011","unstructured":"Sari Y.; Huntington\u2019s disease: From mutant Huntingtin protein to neurotrophic factor therapy. Int J Biomed Sci 2011,7(2),89-100","journal-title":"Int J Biomed Sci"},{"key":"ref=41","doi-asserted-by":"publisher","DOI":"10.5772\/32025","author":"Rossetti G.","year":"2012","unstructured":"Rossetti G.; Magistrato A.; Huntington\u2019s Disease Core Con-cepts Current Advances 2012","journal-title":"Huntington\u2019s Disease Core Con-cepts Current Advances"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1136\/jnnp-2018-318854","volume":"90","author":"Denis H.L.","year":"2019","unstructured":"Denis H.L.; Lamontagne-Proulx J.; St-Amour I.; Mason S.L.; Rowley J.W.; Cloutier N.; Tremblay M.\u00c8.; Vincent A.T.; Gould P.V.; Chouinard S.; Weyrich A.S.; Rondina M.T.; Barker R.A.; Boilard E.; Cicchetti F.; Platelet abnormalities in Huntington\u2019s disease. J Neurol Neurosurg Psychiatry 2019,90(3),272-283","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.neuron.2015.02.026","volume":"85","author":"Huang B.","year":"2015","unstructured":"Huang B.; Wei W.; Wang G.; Gaertig M.A.; Feng Y.; Wang W.; Li X.J.; Li S.; Mutant Huntingtin downregulates myelin regulatory factor-mediated myelin gene expression and affects mature oligodendrocytes. Neuron 2015,85(6),1212-1226","journal-title":"Neuron"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"9622","DOI":"10.1073\/pnas.1818042116","volume":"116","author":"Ferrari Bardile C.","year":"2019","unstructured":"Ferrari Bardile C.; Garcia-Miralles M.; Caron N.S.; Rayan N.A.; Langley S.R.; Harmston N.; Rondelli A.M.; Teo R.T.Y.; Waltl S.; An-derson L.M.; Bae H.G.; Jung S.; Williams A.; Prabhakar S.; Petretto E.; Hayden M.R.; Pouladi M.A.; Intrinsic mutant HTT-mediated de-fects in oligodendroglia cause myelination deficits and behavioral abnormalities in Huntington disease. Proc Natl Acad Sci USA 2019,116(19),9622-9627","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1093\/hmg\/ddy363","volume":"28","author":"Wood T.E.","year":"2019","unstructured":"Wood T.E.; Barry J.; Yang Z.; Cepeda C.; Levine M.S.; Gray M.; Mutant Huntingtin reduction in astrocytes slows disease progression in the BACHD conditional Huntington\u2019s disease mouse model. Hum Mol Genet 2019,28(3),487-500","journal-title":"Hum Mol Genet"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.arr.2018.11.006","volume":"49","author":"Soares T.R.","year":"2019","unstructured":"Soares T.R.; Reis S.D.; Pinho B.R.; Duchen M.R.; Oliveira J.M.A.; Targeting the proteostasis network in Huntington\u2019s disease. Ageing Res Rev 2019,49,92-103","journal-title":"Ageing Res Rev"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1074\/jbc.M114.603332","volume":"290","author":"Monsellier E.","year":"2015","unstructured":"Monsellier E.; Redeker V.; Ruiz-Arlandis G.; Bousset L.; Melki R.; Molecular interaction between the chaperone Hsc70 and the N-terminal flank of Huntingtin exon 1 modulates aggregation. J Biol Chem 2015,290(5),2560-2576","journal-title":"J Biol Chem"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"36","DOI":"10.5607\/en.2014.23.1.36","volume":"23","author":"Kim S.","year":"2014","unstructured":"Kim S.; Kim K-T.; Therapeutic approaches for inhibition of protein aggregation in Huntington\u2019s disease. Exp Neurobiol 2014,23(1),36-44","journal-title":"Exp Neurobiol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.3390\/ijms18071568","volume":"18","author":"Koyuncu S.","year":"2017","unstructured":"Koyuncu S.; Fatima A.; Gutierrez-Garcia R.; Vilchez D.; Proteostasis of Huntingtin in health and disease. Int J Mol Sci 2017,18(7),1568","journal-title":"Int J Mol Sci"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"6709","DOI":"10.1074\/jbc.M113.523696","volume":"289","author":"Tourette C.","year":"2014","unstructured":"Tourette C.; Li B.; Bell R.; O\u2019Hare S.; Kaltenbach L.S.; Mooney S.D.; Hughes R.E.; A large scale Huntingtin protein interaction network implicates Rho GTPase signaling pathways in Huntington disease. J Biol Chem 2014,289(10),6709-6726","journal-title":"J Biol Chem"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3233\/JHD-180311","volume":"8","author":"Tousley A.","year":"2019","unstructured":"Tousley A.; Iuliano M.; Weisman E.; Sapp E.; Zhang N.; Vodicka P.; Alexander J.; Aviolat H.; Gatune L.; Reeves P.; Li X.; Khvo-rova A.; Ellerby L.M.; Aronin N.; DiFiglia M.; Kegel-Gleason K.B.; Rac1 activity is modulated by Huntingtin and dysregulated in models of Huntington\u2019s disease. J Huntingtons Dis 2019,8(1),53-69","journal-title":"J Huntingtons Dis"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.chembiol.2016.11.009","volume":"24","author":"Olzscha H.","year":"2017","unstructured":"Olzscha H.; Fedorov O.; Kessler B.M.; Knapp S.; La Thangue N.B.; CBP\/p300 Bromodomains regulate amyloid-like protein aggregation upon aberrant lysine acetylation. Cell Chem Biol 2017,24(1),9-23","journal-title":"Cell Chem Biol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.nbd.2017.12.015","volume":"111","author":"Dragatsis I.","year":"2018","unstructured":"Dragatsis I.; Dietrich P.; Ren H.; Deng Y.P.; Del Mar N.; Wang H.B.; Johnson I.M.; Jones K.R.; Reiner A.; Effect of early embryonic deletion of Huntingtin from pyramidal neurons on the development and long-term survival of neurons in cerebral cortex and striatum. Neurobiol Dis 2018,111,102-117","journal-title":"Neurobiol Dis"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ymthe.2016.11.010","volume":"25","author":"Monteys A.M.","year":"2017","unstructured":"Monteys A.M.; Ebanks S.A.; Keiser M.S.; Davidson B.L.; CRISPR\/Cas9 editing of the mutant Huntingtin allele in vitro and in vivo. Mol Ther 2017,25(1),12-23","journal-title":"Mol Ther"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.celrep.2017.04.029","volume":"19","author":"Ramdzan Y.M.","year":"2017","unstructured":"Ramdzan Y.M.; Trubetskov M.M.; Ormsby A.R.; Newcombe E.A.; Sui X.; Tobin M.J.; Bongiovanni M.N.; Gras S.L.; Dewson G.; Miller J.M.L.; Finkbeiner S.; Moily N.S.; Niclis J.; Parish C.L.; Purcell A.W.; Baker M.J.; Wilce J.A.; Waris S.; Stojanovski D.; B\u00f6ck-ing T.; Ang C.S.; Ascher D.B.; Reid G.E.; Hatters D.M.; Huntingtin inclusions trigger cellular quiescence, deactivate apoptosis, and lead to delayed necrosis. Cell Rep 2017,19(5),919-927","journal-title":"Cell Rep"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"e266","DOI":"10.1038\/mtna.2015.38","volume":"4","author":"Alterman J.F.","year":"2015","unstructured":"Alterman J.F.; Hall L.M.; Coles A.H.; Hassler M.R.; Didiot M-C.; Chase K.; Abraham J.; Sottosanti E.; Johnson E.; Sapp E.; Osborn M.F.; Difiglia M.; Aronin N.; Khvorova A.; Hydrophobically modified siRNAs silence Huntingtin mRNA in primary neurons and mouse brain. Mol Ther Nucleic Acids 2015,4,e266","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1038\/mtna.2016.7","volume":"5","author":"Miniarikova J.","year":"2016","unstructured":"Miniarikova J.; Zanella I.; Huseinovic A.; van der Zon T.; Hanemaaijer E.; Martier R.; Koornneef A.; Southwell A.L.; Hayden M.R.; van Deventer S.J.; Petry H.; Konstantinova P.; Design, characterization, and lead selection of therapeutic miRNAs targeting Huntingtin for development of gene therapy for Huntington\u2019s disease. Mol Ther Nucleic Acids 2016,5,e297","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.1038\/mtna.2015.20","volume":"4","author":"Grondin R.","year":"2015","unstructured":"Grondin R.; Ge P.; Chen Q.; Sutherland J.E.; Zhang Z.; Gash D.M.; Stiles D.K.; Stewart G.R.; Sah D.W.; Kaemmerer W.F.; Onset time and durability of Huntingtin suppression in rhesus putamen after direct infusion of antiHuntingtin siRNA. Mol Ther Nucleic Acids 2015,4,e245","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"E10809","DOI":"10.1073\/pnas.1705372114","volume":"114","author":"Cariulo C.","year":"2017","unstructured":"Cariulo C.; Azzollini L.; Verani M.; Martufi P.; Boggio R.; Chiki A.; Deguire S.M.; Cherubini M.; Gines S.; Marsh J.L.; Conforti P.; Cattaneo E.; Santimone I.; Squitieri F.; Lashuel H.A.; Petricca L.; Caricasole A.; Phosphorylation of Huntingtin at residue T3 is decreased in Huntington\u2019s disease and modulates mutant Huntingtin protein conformation. Proc Natl Acad Sci USA 2017,114(50),E10809-E10818","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"5070","DOI":"10.1038\/s41598-017-05336-7","volume":"7","author":"Daldin M.","year":"2017","unstructured":"Daldin M.; Fodale V.; Cariulo C.; Azzollini L.; Verani M.; Martufi P.; Spiezia M.C.; Deguire S.M.; Cherubini M.; Macdonald D.; Weiss A.; Bresciani A.; Vonsattel J.G.; Petricca L.; Marsh J.L.; Gines S.; Santimone I.; Marano M.; Lashuel H.A.; Squitieri F.; Cari-casole A.; Polyglutamine expansion affects Huntingtin conformation in multiple Huntington\u2019s disease models. Sci Rep 2017,7(1),5070","journal-title":"Sci Rep"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1172\/JCI80743","volume":"125","author":"Wild E.J.","year":"2015","unstructured":"Wild E.J.; Boggio R.; Langbehn D.; Robertson N.; Haider S.; Miller J.R.C.; Zetterberg H.; Leavitt B.R.; Kuhn R.; Tabrizi S.J.; Macdon-ald D.; Weiss A.; Quantification of mutant Huntingtin protein in cerebrospinal fluid from Huntington\u2019s disease patients. J Clin Invest 2015,125(5),1979-1986","journal-title":"J Clin Invest"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.bbrc.2017.08.126","volume":"493","author":"Zheng J.","year":"2017","unstructured":"Zheng J.; Yang J.; Choe Y-J.; Hao X.; Cao X.; Zhao Q.; Zhang Y.; Franssens V.; Hartl F.U.; Nystr\u00f6m T.; Winderickx J.; Liu B.; Role of the ribosomal quality control machinery in nucleocytoplasmic translocation of polyQ-expanded Huntingtin exon-1. Biochem Biophys Res Commun 2017,493(1),708-717","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cellsig.2016.12.005","volume":"31","author":"Bowles K.R.","year":"2017","unstructured":"Bowles K.R.; Stone T.; Holmans P.; Allen N.D.; Dunnett S.B.; Jones L.; SMAD transcription factors are altered in cell models of HD and regulate HTT expression. Cell Signal 2017,31,1-14","journal-title":"Cell Signal"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1021\/acsomega.7b01472","volume":"3","author":"Chaibva M.","year":"2018","unstructured":"Chaibva M.; Gao X.; Jain P.; Campbell W.A.; Frey S.L.; Legleiter J.; Sphingomyelin and GM1 influence Huntingtin binding to, dis-ruption of, and aggregation on lipid membranes. ACS Omega 2018,3(1),273-285","journal-title":"ACS Omega"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1172\/JCI83185","volume":"126","author":"Ru\u00e9 L.","year":"2016","unstructured":"Ru\u00e9 L.; Ba\u00f1ez-Coronel M.; Creus-Muncunill J.; Giralt A.; Alcal\u00e1-Vida R.; Mentxaka G.; Kagerbauer B.; Zome\u00f1o-Abell\u00e1n M.T.; Aranda Z.; Venturi V.; P\u00e9rez-Navarro E.; Estivill X.; Mart\u00ed E.; Targeting CAG repeat RNAs reduces Huntington\u2019s disease phenotype independent-ly of Huntingtin levels. J Clin Invest 2016,126(11),4319-4330","journal-title":"J Clin Invest"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ajhg.2015.12.018","volume":"98","author":"Keum J.W.","year":"2016","unstructured":"Keum J.W.; Shin A.; Gillis T.; Mysore J.S.; Abu Elneel K.; Lucente D.; Hadzi T.; Holmans P.; Jones L.; Orth M.; Kwak S.; MacDon-ald M.E.; Gusella J.F.; Lee J.M.; The HTT CAG-expansion mutation determines age at death but not disease duration in Huntington dis-ease. Am J Hum Genet 2016,98(2),287-298","journal-title":"Am J Hum Genet"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1601.e7","DOI":"10.1016\/j.neurobiolaging.2014.11.014","volume":"36","author":"Francelle L.","year":"2015","unstructured":"Francelle L.; Galvan L.; Gaillard M-C.; Petit F.; Bernay B.; Guillermier M.; Bonvento G.; Dufour N.; Elalouf J.M.; Hantraye P.; D\u00e9-glon N.; de Chald\u00e9e M.; Brouillet E.; Striatal long noncoding RNA Abhd11os is neuroprotective against an N-terminal fragment of mutant Huntingtin in vivo. Neurobiol Aging 2015,36(3),1601.e7-1601.e16","journal-title":"Neurobiol Aging"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1038\/s41598-017-01510-z","volume":"7","author":"Neueder A.","year":"2017","unstructured":"Neueder A.; Landles C.; Ghosh R.; Howland D.; Myers R.H.; Faull R.L.M.; Tabrizi S.J.; Bates G.P.; The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington\u2019s disease patients. Sci Rep 2017,7(1),1307","journal-title":"Sci Rep"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"4406","DOI":"10.1073\/pnas.1702237114","volume":"114","author":"Chen M.","year":"2017","unstructured":"Chen M.; Wolynes P.G.; Aggregation landscapes of Huntingtin exon 1 protein fragments and the critical repeat length for the onset of Hun-tington\u2019s disease. Proc Natl Acad Sci USA 2017,114(17),4406-4411","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1515\/bmc-2015-0001","volume":"6","author":"Arndt J.R.","year":"2015","unstructured":"Arndt J.R.; Chaibva M.; Legleiter J.; The emerging role of the first 17 amino acids of Huntingtin in Huntington\u2019s disease. Biomol Concepts 2015,6(1),33-46","journal-title":"Biomol Concepts"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/j.jmb.2018.03.017","volume":"430","author":"Wagner A.S.","year":"2018","unstructured":"Wagner A.S.; Politi A.Z.; Ast A.; Bravo-Rodriguez K.; Baum K.; Buntru A.; Strempel N.U.; Brusendorf L.; H\u00e4nig C.; Boeddrich A.; Plassmann S.; Klockmeier K.; Ramirez-Anguita J.M.; Sanchez-Garcia E.; Wolf J.; Wanker E.E.; Self-assembly of Mutant Huntingtin Ex-on-1 fragments into large complex fibrillar structures involves nucleated branching. J Mol Biol 2018,430(12),1725-1744","journal-title":"J Mol Biol"},{"key":"ref=72","first-page":"195297","author":"Wagner A.S.","year":"2017","unstructured":"Wagner A.S.; Politi A.Z.; Steinhof A.; Bravo-Rodriguez K.; Buntru A.; Strempel N.U.; Fibril branching dominates self-assembly of mu-tant Huntingtin exon-1 aggregates in vitro. BioRxiv 2017,195297","journal-title":"BioRxiv"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"Morris G.M.","year":"2009","unstructured":"Morris G.M.; Huey R.; Lindstrom W.; Sanner M.F.; Belew R.K.; Goodsell D.S.; Olson A.J.; AutoDock4 and AutoDockTools4: Auto-mated docking with selective receptor flexibility. J Comput Chem 2009,30(16),2785-2791","journal-title":"J Comput Chem"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/jmcb\/mju007","volume":"6","author":"Redler R.L.","year":"2014","unstructured":"Redler R.L.; Shirvanyants D.; Dagliyan O.; Ding F.; Kim D.N.; Kota P.; Proctor E.A.; Ramachandran S.; Tandon A.; Dokholyan N.V.; Computational approaches to understanding protein aggregation in neurodegeneration. J Mol Cell Biol 2014,6(2),104-115","journal-title":"J Mol Cell Biol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"6247867","DOI":"10.1155\/2016\/6247867","volume":"2016","author":"Smaoui M.R.","year":"2016","unstructured":"Smaoui M.R.; Mazza-Anthony C.; Waldisp\u00fchl J.; Investigating mutations to reduce Huntingtin aggregation by increasing Htt-N-terminal stability and weakening interactions with PolyQ domain. Comput Math Methods Med 2016,2016,6247867","journal-title":"Comput Math Methods Med"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"606172","DOI":"10.1155\/2012\/606172","volume":"2012","author":"Ch\u00e1nez-C\u00e1rdenas M.E.","year":"2012","unstructured":"Ch\u00e1nez-C\u00e1rdenas M.E.; V\u00e1zquez-Contreras E.; The aggregation of Huntingtin and","journal-title":"J Biophys"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.cplett.2018.12.042","volume":"717","author":"Srinivasan E.","year":"2019","unstructured":"Srinivasan E.; Rajasekaran R.; Effect of","journal-title":"Chem Phys Lett"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1016\/j.jmb.2014.07.016","volume":"426","author":"Nedd S.","year":"2014","unstructured":"Nedd S.; Redler R.L.; Proctor E.A.; Dokholyan N.V.; Alexandrova A.N.; Cu,Zn-superoxide dismutase without Zn is folded but catalyti-cally inactive. J Mol Biol 2014,426(24),4112-4124","journal-title":"J Mol Biol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/wcms.4","volume":"1","author":"Proctor E.A.","year":"2011","unstructured":"Proctor E.A.; Ding F.; Dokholyan N.V.; Discrete molecular dynamics. Wiley Interdiscip Rev Comput Mol Sci 2011,1(1),80-92","journal-title":"Wiley Interdiscip Rev Comput Mol Sci"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"8375","DOI":"10.1021\/jp2114576","volume":"116","author":"Shirvanyants D.","year":"2012","unstructured":"Shirvanyants D.; Ding F.; Tsao D.; Ramachandran S.; Dokholyan N.V.; Discrete molecular dynamics: An efficient and versatile simula-tion method for fine protein characterization. J Phys Chem B 2012,116(29),8375-8382","journal-title":"J Phys Chem B"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.sbi.2015.11.001","volume":"37","author":"Proctor E.A.","year":"2016","unstructured":"Proctor E.A.; Dokholyan N.V.; Applications of discrete molecular dynamics in biology and medicine. Curr Opin Struct Biol 2016,37,9-13","journal-title":"Curr Opin Struct Biol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"e1000772","DOI":"10.1371\/journal.pcbi.1000772","volume":"6","author":"Lakhani V.V.","year":"2010","unstructured":"Lakhani V.V.; Ding F.; Dokholyan N.V.; Polyglutamine induced misfolding of Huntingtin exon1 is modulated by the flanking sequences. PLOS Comput Biol 2010,6(4),e1000772","journal-title":"PLOS Comput Biol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1002\/prot.25288","volume":"85","author":"Srinivasan E.","year":"2017","unstructured":"Srinivasan E.; Rajasekaran R.; Exploring the cause of aggregation and reduced Zn binding affinity by G85R mutation in SOD1 rendering amyotrophic lateral sclerosis: In silico study on SOD1 mutant G85R. Proteins Struct Funct Bioinforma 2017,85,1276-1286","journal-title":"Proteins Struct Funct Bioinforma"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.pbiomolbio.2018.12.003","volume":"145","author":"Srinivasan E.","year":"2019","unstructured":"Srinivasan E.; Rajasekaran R.; Molecular binding response of naringin and naringenin to H46R mutant SOD1 protein in combating protein aggregation using density functional theory and discrete molecular dynamics. Prog Biophys Mol Biol 2019,145,40-51","journal-title":"Prog Biophys Mol Biol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"116425","DOI":"10.1016\/j.jns.2019.116425","volume":"405","author":"Srinivasan E.","year":"2019","unstructured":"Srinivasan E.; Rajasekaran R.; Rational design of linear tripeptides against the aggregation of human mutant SOD1 protein causing amyo-trophic lateral sclerosis. J Neurol Sci 2019,405,116425","journal-title":"J Neurol Sci"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/978-1-4939-7811-3_5","volume":"1777","author":"Qi R.","year":"2018","unstructured":"Qi R.; Wei G.; Ma B.; Nussinov R.; Replica exchange molecular dynamics: A practical application protocol with solutions to common problems and a peptide aggregation and self-assembly example. Methods Mol Biol 2018,1777,101-119","journal-title":"Methods Mol Biol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1007\/s00894-012-1712-9","volume":"19","author":"Nakano M.","year":"2013","unstructured":"Nakano M.; Ebina K.; Tanaka S.; Study of the aggregation mechanism of polyglutamine peptides using replica exchange molecular dynam-ics simulations. J Mol Model 2013,19(4),1627-1639","journal-title":"J Mol Model"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.bpj.2016.01.015","volume":"110","author":"Binette V.","year":"2016","unstructured":"Binette V.; C\u00f4t\u00e9 S.; Mousseau N.; Free-energy landscape of the amino-terminal fragment of Huntingtin in aqueous solution. Biophys J 2016,110(5),1075-1088","journal-title":"Biophys J"},{"key":"ref=89","doi-asserted-by":"publisher","DOI":"10.5772\/1470","author":"Tunal\u0131 N.E","year":"2012","unstructured":"Tunal\u0131 N.E; Huntington\u2019s Disease: Core Concepts and Current Advances BoD \u2013 Books on Demand 2012","journal-title":"BoD \u2013 Books on Demand"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"710","DOI":"10.3389\/fneur.2019.00710","volume":"10","author":"Bachoud-L\u00e9vi A-C.","year":"2019","unstructured":"Bachoud-L\u00e9vi A-C.; Ferreira J.; Massart R.; Youssov K.; Rosser A.; Busse M.; Craufurd D.; Reilmann R.; De Michele G.; Rae D.; Squitieri F.; Seppi K.; Perrine C.; Scherer-Gagou C.; Audrey O.; Verny C.; Burgunder J.M.; International guidelines for the treatment of Huntington\u2019s disease. Front Neurol 2019,10,710","journal-title":"Front Neurol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/ene.13413","volume":"25","author":"McColgan P.","year":"2018","unstructured":"McColgan P.; Tabrizi S.J.; Huntington\u2019s disease: A clinical review. Eur J Neurol 2018,25(1),24-34","journal-title":"Eur J Neurol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/mds.26331","volume":"30","author":"Shannon K.M.","year":"2015","unstructured":"Shannon K.M.; Fraint A.; Therapeutic advances in Huntington\u2019s disease. Mov Disord 2015,30(11),1539-1546","journal-title":"Mov Disord"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40265-016-0670-4","volume":"77","author":"Coppen E.M.","year":"2017","unstructured":"Coppen E.M.; Roos R.A.C.; Current pharmacological approaches to reduce chorea in Huntington\u2019s disease. Drugs 2017,77(1),29-46","journal-title":"Drugs"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s13311-014-0304-z","volume":"12","author":"Valdeolivas S.","year":"2015","unstructured":"Valdeolivas S.; Navarrete C.; Cantarero I.; Bellido M.L.; Mu\u00f1oz E.; Sagredo O.; Neuroprotective properties of cannabigerol in Hunting-ton\u2019s disease: Studies in R6\/2 mice and 3-nitropropionate-lesioned mice. Neurotherapeutics 2015,12(1),185-199","journal-title":"Neurotherapeutics"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1002\/mds.26260","volume":"30","author":"Raja M.","year":"2015","unstructured":"Raja M.; Soleti F.; Bentivoglio A.R.; Lithium treatment in patients with Huntington\u2019s disease and suicidal behavior. Mov Disord 2015,30(10),1438","journal-title":"Mov Disord"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s13311-013-0244-z","volume":"11","author":"Frank S.","year":"2014","unstructured":"Frank S.; Treatment of Huntington\u2019s disease. Neurotherapeutics 2014,11(1),153-160","journal-title":"Neurotherapeutics"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"e0173872","DOI":"10.1371\/journal.pone.0173872","volume":"12","author":"Gelderblom H.","year":"2017","unstructured":"Gelderblom H.; W\u00fcstenberg T.; McLean T.; M\u00fctze L.; Fischer W.; Saft C.; Hoffmann R.; S\u00fcssmuth S.; Schlattmann P.; van Duijn E.; Landwehrmeyer B.; Priller J.; Bupropion for the treatment of apathy in Huntington\u2019s disease: A multicenter, randomised, double-blind, pla-cebo-controlled, prospective crossover trial. PLoS One 2017,12(3),e0173872","journal-title":"PLoS One"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"e38744","DOI":"10.7554\/eLife.38744","volume":"7","author":"Arnoux I.","year":"2018","unstructured":"Arnoux I.; Willam M.; Griesche N.; Krummeich J.; Watari H.; Offermann N.; Weber S.; Narayan Dey P.; Chen C.; Monteiro O.; Buett-ner S.; Meyer K.; Bano D.; Radyushkin K.; Langston R.; Lambert J.J.; Wanker E.; Methner A.; Krauss S.; Schweiger S.; Stroh A.; Metformin reverses early cortical network dysfunction and behavior changes in Huntington\u2019s disease. eLife 2018,7,e38744","journal-title":"eLife"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/hmg\/ddw045","volume":"25","author":"Yin X.","year":"2016","unstructured":"Yin X.; Manczak M.; Reddy P.H.; Mitochondria-targeted molecules MitoQ and SS31 reduce mutant Huntingtin-induced mitochondrial toxicity and synaptic damage in Huntington\u2019s disease. Hum Mol Genet 2016,25(9),1739-1753","journal-title":"Hum Mol Genet"},{"key":"ref=100","doi-asserted-by":"publisher","DOI":"10.20944\/preprints201912.0261.v1","author":"Kumar A.","year":"2019","unstructured":"Kumar A.; Kumar V.; Singh K.; Kim Y.-S.; Lee Y.-M.; Kim J.-J.; Therapeutics advancement for huntington disease. Med Pharmacol 2019","journal-title":"Med Pharmacol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s12035-019-01847-8","volume":"57","author":"Paldino E.","year":"2020","unstructured":"Paldino E.; Balducci C.; La Vitola P.; Artioli L.; D\u2019Angelo V.; Giamp\u00e0 C.; Artuso V.; Forloni G.; Fusco F.R.; Neuroprotective effects of doxycycline in the r6\/2 mouse model of Huntington\u2019s disease. Mol Neurobiol 2020,57(4),1889-1903","journal-title":"Mol Neurobiol"},{"key":"ref=102","year":"2021","unstructured":"A phase 3, randomized, double-blind, placebo-controlled, parallel arm, multicenter study evaluating the efficacy and safety of pridopidine in patients with early stage of huntington disease. Available from: Prilenia2021 http:\/\/clinicaltrials.gov"},{"key":"ref=103","year":"2021","unstructured":"A anaplerotic therapy in Huntington\u2019s disease Institut National de la Sant\u00e9 Et de la Recherche M\u00e9dicale2021 http:\/\/clinicaltrials.gov"},{"key":"ref=104","year":"2008","unstructured":"NMDA-receptor blockade in Huntington\u2019s Chorea. Available from: National Institute of Neurological Disorders and Stroke (NINDS)2008 http:\/\/clinicaltrials.gov"},{"key":"ref=105","year":"2020","unstructured":"An open label, phase Ib study to evaluate the impact of low doses of nilotinib treatment on safety, tolerability and biomarkers in Huntington\u2019s disease. MD KEA2020 http:\/\/clinicaltrials.gov"},{"key":"ref=106","author":"Brown A.E.","year":"2021","unstructured":"Brown A.E.; Impact of deutetrabenazine on functional speech and gait dynamics in huntington disease 2021 http:\/\/clinicaltrials.gov","journal-title":"Impact of deutetrabenazine on functional speech and gait dynamics in huntington disease"},{"key":"ref=107","year":"2021","unstructured":"Non-randomized control clinical trial to evaluate the efficacy and safe-ty of symptomatic drug therapy for mild to moderate Huntington\u2019s disease patients. Available from: Second Affiliated Hospital, School of Medicine, Zhejiang University2021 http:\/\/clinicaltrials.gov"},{"key":"ref=108","year":"2021","unstructured":"A phase IIa, randomized, doubleblind, placebo-controlled study of the safety and efficacy of fenofibrate as a treatment for Huntington\u2019s disease. Available from: University of California Irvine2021 http:\/\/clinicaltrials.gov"},{"key":"ref=109","year":"2019","unstructured":"MD WO Available from: 2019"},{"key":"ref=110","unstructured":"Risperidone for the treatment of Huntington\u2019s disease chorea MD RSAvailable from: 2021.","journal-title":"Risperidone for the treatment of Huntington\u2019s disease chorea"},{"key":"ref=111","unstructured":"Ursodiol in Huntington\u2019s Disease Oregon Health and Science UniversityAvailable from: 2009.","journal-title":"Ursodiol in Huntington\u2019s Disease"},{"key":"ref=112","unstructured":"A multicenter, multinational, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of laquinimod (0.5, 1.0 and 1.5 mg\/day) as treatment in patients with Huntington\u2019s disease Teva Branded Pharmaceutical Products R"},{"key":"ref=113","author":"Stimming E.F.","unstructured":"Stimming E.F.; Evaluating the efficacy of dextromethorphan\/ quinidine in treating irritability in Huntington\u2019s disease Available from: 2021."},{"key":"ref=114","year":"2021","unstructured":"Open-label rollover study for continuing valbenazine administration for the treatment of chorea associated with Huntington disease. Neurocrine Biosciences2021 http:\/\/clinicaltrials.gov"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S1474-4422(18)30391-0","volume":"18","author":"Reilmann R.","year":"2019","unstructured":"Reilmann R.; McGarry A.; Grachev I.D.; Savola J-M.; Borowsky B.; Eyal E.; Gross N.; Langbehn D.; Schubert R.; Wickenberg A.T.; Papapetropoulos S.; Hayden M.; Squitieri F.; Kieburtz K.; Landwehrmeyer G.B.; Agarwal P.; Anderson K.E.; Aziz N.A.; Azulay J-P.; Bachoud-Levi A.C.; Barker R.; Bebak A.; Beuth M.; Biglan K.; Blin S.; Bohlen S.; Bonelli R.; Caldwell S.; Calvas F.; Carlos J.; Casta-gliuolo S.; Chong T.; Chua P.; Coleman A.; Corey-Bloom J.; Cousins R.; Craufurd D.; Davison J.; Decorte E.; De Michele G.; Dorn-hege L.; Feigin A.; Gallehawk S.; Gauteul P.; Gonzales C.; Griffith J.; Gustov A.; Guttman M.; Heim B.; Heller H.; Hjermind L.; Illar-ioshkin S.; Ivanko L.; Jaynes J.; Jenckes M.; Kaminski B.; Kampstra A.; Konkel A.; Kopishinskaya S.; Krystkowiak P.; Komati S.K.; Kwako A.; Lakoning S.; Latipova G.; Leavitt B.; Loy C.; MacFarlane C.; Madsen L.; Marder K.; Mason S.; Mendis N.; Mendis T.; Nemeth A.; Nevitt L.; Norris V.; O\u2019Neill C.; Olivier A.; Orth M.; Owens A.; Panegyres P.; Perlman S.; Preston J.; Priller J.; Puch A.; Quarrell O.; Ragosta D.; Rialland A.; Rickards H.; Romoli A.M.; Ross C.; Rosser A.; Rudzinska M.; Russo C.V.; Saft C.; Segro V.; Seppi K.; Shannon B.; Shprecher D.; Simonin C.; Skitt Z.; Slawek J.; Soliveri P.; Sorbi S.; Squitieri F.; Suski V.; Stepniak I.; Sungmee P.; Temirbaeva S.; Testa C.; Torvin-Moller A.; Uhl S.; Vangsted-Hansen C.; Verny C.; Wall P.; Walker F.; Wasserman P.; Witkowski G.; Wright J.; Zalyalova Z.; Zielonka D.; Safety and efficacy of pridopidine in patients with Huntington\u2019s disease (PRIDE-HD): A phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. Lancet Neurol 2019,18(2),165-176","journal-title":"Lancet Neurol"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13041-019-0456-1","volume":"12","author":"Abd-Elrahman K.S.","year":"2019","unstructured":"Abd-Elrahman K.S.; Ferguson S.S.G.; Modulation of mTOR and CREB pathways following mGluR5 blockade contribute to improved Hun-tington\u2019s pathology in zQ175 mice. Mol Brain 2019,12(1),35","journal-title":"Mol Brain"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"104560","DOI":"10.1016\/j.nbd.2019.104560","volume":"132","author":"Sj\u00f6gren M.","year":"2019","unstructured":"Sj\u00f6gren M.; Soylu-Kucharz R.; Dandunna U.; Stan T.L.; Cavalera M.; Sandelius \u00c5.; Zetterberg H.; Bj\u00f6rkqvist M.; Leptin deficiency reverses high metabolic state and weight loss without affecting central pathology in the R6\/2 mouse model of Huntington\u2019s disease. Neurobiol Dis 2019,132,104560","journal-title":"Neurobiol Dis"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1172\/JCI120616","volume":"129","author":"Vezzoli E.","year":"2019","unstructured":"Vezzoli E.; Caron I.; Talpo F.; Besusso D.; Conforti P.; Battaglia E.; Sogne E.; Falqui A.; Petricca L.; Verani M.; Martufi P.; Cari-casole A.; Bresciani A.; Cecchetti O.; Rivetti di Val Cervo P.; Sancini G.; Riess O.; Nguyen H.; Seipold L.; Saftig P.; Biella G.; Catta-neo E.; Zuccato C.; Inhibiting pathologically active ADAM10 rescues synaptic and cognitive decline in Huntington\u2019s disease. J Clin Invest 2019,129(6),2390-2403","journal-title":"J Clin Invest"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.nbd.2015.01.002","volume":"76","author":"Southwell A.L.","year":"2015","unstructured":"Southwell A.L.; Franciosi S.; Villanueva E.B.; Xie Y.; Winter L.A.; Veeraraghavan J.; Jonason A.; Felczak B.; Zhang W.; Kovalik V.; Waltl S.; Hall G.; Pouladi M.A.; Smith E.S.; Bowers W.J.; Zauderer M.; Hayden M.R.; Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease. Neurobiol Dis 2015,76,46-56","journal-title":"Neurobiol Dis"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"4328","DOI":"10.1093\/hmg\/ddu151","volume":"23","author":"Hsiao H-Y.","year":"2014","unstructured":"Hsiao H-Y.; Chiu F-L.; Chen C-M.; Wu Y-R.; Chen H-M.; Chen Y-C.; Kuo H.C.; Chern Y.; Inhibition of soluble tumor necrosis factor is therapeutic in Huntington\u2019s disease. Hum Mol Genet 2014,23(16),4328-4344","journal-title":"Hum Mol Genet"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3389\/fimmu.2020.00337","volume":"11","author":"Fatoba O.","year":"2020","unstructured":"Fatoba O.; Ohtake Y.; Itokazu T.; Yamashita T.; Immunotherapies in Huntington\u2019s disease and \u03b1-synucleinopathies. Front Immunol 2020,11,337","journal-title":"Front Immunol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1517\/14656566.2016.1109630","volume":"17","author":"Mason S.L.","year":"2016","unstructured":"Mason S.L.; Barker R.A.; Advancing pharmacotherapy for treating Huntington\u2019s disease: A review of the existing literature. Expert Opin Pharmacother 2016,17(1),41-52","journal-title":"Expert Opin Pharmacother"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.omtn.2019.07.009","volume":"17","author":"Ekman F.K.","year":"2019","unstructured":"Ekman F.K.; Ojala D.S.; Adil M.M.; Lopez P.A.; Schaffer D.V.; Gaj T.; CRISPR-Cas9-mediated genome editing increases lifespan and improves motor deficits in a Huntington\u2019s disease mouse model. Mol Ther Nucleic Acids 2019,17,829-839","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.neuron.2019.01.039","volume":"101","author":"Tabrizi S.J.","year":"2019","unstructured":"Tabrizi S.J.; Ghosh R.; Leavitt B.R.; Huntingtin lowering strategies for disease modification in Huntington\u2019s disease. Neuron 2019,101(5),801-819","journal-title":"Neuron"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.drudis.2014.09.011","volume":"20","author":"Godinho B.M.D.C.","year":"2015","unstructured":"Godinho B.M.D.C.; Malhotra M.; O\u2019Driscoll C.M.; Cryan J.F.; Delivering a disease-modifying treatment for Huntington\u2019s disease. Drug Discov Today 2015,20(1),50-64","journal-title":"Drug Discov Today"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/s41591-019-0478-3","volume":"25","author":"Zeitler B.","year":"2019","unstructured":"Zeitler B.; Froelich S.; Marlen K.; Shivak D.A.; Yu Q.; Li D.; Pearl J.R.; Miller J.C.; Zhang L.; Paschon D.E.; Hinkley S.J.; Ankoudi-nova I.; Lam S.; Guschin D.; Kopan L.; Cherone J.M.; Nguyen H.B.; Qiao G.; Ataei Y.; Mendel M.C.; Amora R.; Surosky R.; Laga-niere J.; Vu B.J.; Narayanan A.; Sedaghat Y.; Tillack K.; Thiede C.; G\u00e4rtner A.; Kwak S.; Bard J.; Mrzljak L.; Park L.; Heikkinen T.; Lehtim\u00e4ki K.K.; Svedberg M.M.; H\u00e4ggkvist J.; Tari L.; T\u00f3th M.; Varrone A.; Halldin C.; Kudwa A.E.; Ramboz S.; Day M.; Kondapal-li J.; Surmeier D.J.; Urnov F.D.; Gregory P.D.; Rebar E.J.; Mu\u00f1oz-Sanju\u00e1n I.; Zhang H.S.; Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington\u2019s disease. Nat Med 2019,25(7),1131-1142","journal-title":"Nat Med"},{"key":"ref=127","year":"2021","unstructured":"An open-label extension study to evaluate the long-term safety and tolerability of intrathecally administered RO7234292 (RG6042) in patients with Huntington\u2019s disease Hoffmann-La Roche2021 Available from: http:\/\/clinicaltrials.gov"},{"key":"ref=128","year":"2021","unstructured":"Brasil, Azidus First in human study to evaluate safety of cellavita hd investigational product after intravenous application in participants with Huntington\u2019s disease 2021 Available from: http:\/\/clinicaltrials.gov"},{"key":"ref=129","year":"2021","unstructured":"Brasil, Azidus Clinical extension study for assessing the safety and efficacy of the intravenous administration of cellavita-HD in Huntington\u2019s disease patients who participated in the ADORE-DH study. 2021 Available from: http:\/\/clinicaltrials.gov"},{"key":"ref=130","first-page":"2307","volume":"380","author":"Tabrizi S.","year":"2019","unstructured":"Tabrizi S.; Leavitt B.; Kordasiewicz H.; Czech C.; Swayze E.; Norris D.A.; Effects of IONIS-HTTRx in Patients with Early Huntington\u2019s Disease, Results of the First HTT-Lowering Drug Trial (CT.002). Neurology 2019,380(24),2307-2316","journal-title":"Neurology"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jmgm.2017.04.019","volume":"74","author":"Srinivasan E.","year":"2017","unstructured":"Srinivasan E.; Rajasekaran R.; Probing the inhibitory activity of epigallocatechin-gallate on toxic aggregates of mutant (L84F) SOD1 protein through geometry based sampling and steered molecular dynamics. J Mol Graph Model 2017,74,288-295","journal-title":"J Mol Graph Model"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1080\/08927022.2019.1660778","volume":"45","author":"Srinivasan E.","year":"2019","unstructured":"Srinivasan E.; Ravikumar S.; Venkataramanan S.; Purohit R.; Rajasekaran R.; Molecular mechanics and quantum chemical calculations unveil the combating effect of baicalein on human islet amyloid polypeptide aggregates. Mol Simul 2019,45(18),1538-1548","journal-title":"Mol Simul"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1007\/s10822-018-0175-1","volume":"32","author":"Srinivasan E.","year":"2018","unstructured":"Srinivasan E.; Rajasekaran R.; Quantum chemical and molecular mechanics studies on the assessment of interactions between resveratrol and mutant SOD1 (G93A) protein. J Comput Aided Mol Des 2018,32(12),1347-1361","journal-title":"J Comput Aided Mol Des"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1007\/s12031-020-01569-w","volume":"70","author":"Srinivasan E.","year":"2020","unstructured":"Srinivasan E.; Rajasekaran R.; A systematic and comprehensive review on disease-causing genes in amyotrophic lateral sclerosis. J Mol Neurosci 2020,70(11),1742-1770","journal-title":"J Mol Neurosci"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1039\/C7MB00106A","volume":"13","author":"Srinivasan E.","year":"2017","unstructured":"Srinivasan E.; Rajasekaran R.; Computational investigation of the human SOD1 mutant, Cys146Arg, that directs familial amyotrophic lat-eral sclerosis. Mol Biosyst 2017,13(8),1495-1503","journal-title":"Mol Biosyst"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/biof.1441","volume":"44","author":"Srinivasan E.","year":"2018","unstructured":"Srinivasan E.; Rajasekaran R.; Comparative binding of kaempferol and kaempferide on inhibiting the aggregate formation of mutant (G85R) SOD1 protein in familial amyotrophic lateral sclerosis: A quantum chemical and molecular mechanics study. Biofactors 2018,44(5),431-442","journal-title":"Biofactors"},{"key":"ref=137","first-page":"175","volume":"17","author":"Yassa N.","year":"2015","unstructured":"Yassa N.; Masoomi F.; Rankouhi S.E.R.; Hadjiakhoondi A.; Chemical composition and antioxidant activity of the extract and essential oil of Rosa damascena from Iran, population of guilan. Daru 2015,17,175-180","journal-title":"Daru"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1001\/jama.2011.1360","volume":"306","author":"Maher A.R.","year":"2011","unstructured":"Maher A.R.; Maglione M.; Bagley S.; Suttorp M.; Hu J-H.; Ewing B.; Wang Z.; Timmer M.; Sultzer D.; Shekelle P.G.; Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: A systematic review and meta-analysis. JAMA 2011,306(12),1359-1369","journal-title":"JAMA"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1002\/jnr.22017","volume":"87","author":"Wu J.","year":"2009","unstructured":"Wu J.; Jeong H.K.; Bulin S.E.; Kwon S.W.; Park J.H.; Bezprozvanny I.; Ginsenosides protect striatal neurons in a cellular model of Hun-tington\u2019s disease. J Neurosci Res 2009,87(8),1904-1912","journal-title":"J Neurosci Res"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/1472-6882-13-121","volume":"13","author":"Ali S.K.","year":"2013","unstructured":"Ali S.K.; Hamed A.R.; Soltan M.M.; Hegazy U.M.; Elgorashi E.E.; El-Garf I.A.; Hussein A.A.; In-vitro evaluation of selected Egyptian traditional herbal medicines for treatment of Alzheimer disease. BMC Complement Altern Med 2013,13(1),121","journal-title":"BMC Complement Altern Med"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/j.1471-4159.2009.06331.x","volume":"111","author":"Lagoa R.","year":"2009","unstructured":"Lagoa R.; Lopez-Sanchez C.; Samhan-Arias A.K.; Ga\u00f1an C.M.; Garcia-Martinez V.; Gutierrez-Merino C.; Kaempferol protects against rat striatal degeneration induced by 3-nitropropionic acid. J Neurochem 2009,111(2),473-487","journal-title":"J Neurochem"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1089\/jmf.2012.2698","volume":"16","author":"Binawade Y.","year":"2013","unstructured":"Binawade Y.; Jagtap A.; Neuroprotective effect of lutein against 3-nitropropionic acid-induced Huntington\u2019s disease-like symptoms: possi-ble behavioral, biochemical, and cellular alterations. J Med Food 2013,16(10),934-943","journal-title":"J Med Food"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/j.1600-079X.2004.00163.x","volume":"37","author":"T\u00fanez I.","year":"2004","unstructured":"T\u00fanez I.; Montilla P.; Del Carmen Mu\u00f1oz M.; Feij\u00f3o M.; Salcedo M.; Protective effect of melatonin on 3-nitropropionic acid-induced oxidative stress in synaptosomes in an animal model of Huntington\u2019s disease. J Pineal Res 2004,37(4),252-256","journal-title":"J Pineal Res"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ejphar.2009.04.058","volume":"615","author":"Kumar P.","year":"2009","unstructured":"Kumar P.; Kumar A.; Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntington\u2019s disease like symptoms: possible behavioural, biochemical and cellular alterations. Eur J Pharmacol 2009,615(1-3),91-101","journal-title":"Eur J Pharmacol"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/aps.2014.107","volume":"36","author":"Gao Y.","year":"2015","unstructured":"Gao Y.; Chu S.F.; Li J.P.; Zhang Z.; Yan J.Q.; Wen Z.L.; Xia C.Y.; Mou Z.; Wang Z.Z.; He W.B.; Guo X.F.; Wei G.N.; Chen N.H.; Protopanaxtriol protects against 3-nitropropionic acid-induced oxidative stress in a rat model of Huntington\u2019s disease. Acta Pharmacol Sin 2015,36(3),311-322","journal-title":"Acta Pharmacol Sin"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-016-0779-0","volume":"14","author":"Moussa C.","year":"2017","unstructured":"Moussa C.; Hebron M.; Huang X.; Ahn J.; Rissman R.A.; Aisen P.S.; Turner R.S.; Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer\u2019s disease. J Neuroinflammation 2017,14(1),1","journal-title":"J Neuroinflammation"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.etp.2008.11.002","volume":"61","author":"Pedraza-Chaverr\u00ed J.","year":"2009","unstructured":"Pedraza-Chaverr\u00ed J.; Reyes-Ferm\u00edn L.M.; Nolasco-Amaya E.G.; Orozco-Ibarra M.; Medina-Campos O.N.; Gonz\u00e1lez-Cuahutencos O.; Rivero-Cruz I.; Mata R.; ROS scavenging capacity and neuroprotective effect of alpha-mangostin against 3-nitropropionic acid in cerebellar granule neurons. Exp Toxicol Pathol Off J Ges Toxikol Pathol 2009,61(5),491-501","journal-title":"Exp Toxicol Pathol Off J Ges Toxikol Pathol"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3389\/fphys.2020.00361","volume":"11","author":"Momtaz S.","year":"2020","unstructured":"Momtaz S.; Memariani Z.; El-Senduny F.F.; Sanadgol N.; Golab F.; Katebi M.; Abdolghaffari A.H.; Farzaei M.H.; Abdollahi M.; Tar-geting ubiquitin-proteasome pathway by natural products: novel therapeutic strategy for treatment of neurodegenerative diseases. Front Physiol 2020,11,361","journal-title":"Front Physiol"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/j.1600-0447.2011.01713.x","volume":"124","author":"Vanmierlo T.","year":"2011","unstructured":"Vanmierlo T.; Popp J.; K\u00f6lsch H.; Friedrichs S.; Jessen F.; Stoffel-Wagner B.; Bertsch T.; Hartmann T.; Maier W.; von Bergmann K.; Steinbusch H.; Mulder M.; L\u00fctjohann D.; The plant sterol brassicasterol as additional CSF biomarker in Alzheimer\u2019s disease. Acta Psychiatr Scand 2011,124(3),184-192","journal-title":"Acta Psychiatr Scand"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"24460","DOI":"10.1074\/jbc.M112.382226","volume":"287","author":"Fu J.","year":"2012","unstructured":"Fu J.; Jin, J.; Cichewicz, R.H.; Hageman, S.A.; Ellis, T.K.; Xiang, L.; Peng, Q.; Jiang, M.; Arbez, N.; Hotaling, K.; Ross, C.A.; Duan, W. trans-(-)-","journal-title":"J Biol Chem"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1028415X.2020.1721645","author":"Salman M.","year":"2020","unstructured":"Salman M.; Tabassum H.; Parvez S.; Piperine mitigates behavioral impairments and provides neuroprotection against 3-nitropropinoic acid-induced Huntington disease-like symptoms. Nutr Neurosci 2020,1-10","journal-title":"Nutr Neurosci"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s11011-019-00405-4","volume":"34","author":"Pierzynowska K.","year":"2019","unstructured":"Pierzynowska K.; Gaffke L.; Cyske Z.; W","journal-title":"Metab Brain Dis"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s12017-018-8482-1","volume":"20","author":"Pierzynowska K.","year":"2018","unstructured":"Pierzynowska K.; Gaffke L.; Ha& A.; Mantej, J.; Niedzia&ek, N.; Brokowska, J.; W","journal-title":"Neuromolecular Med"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/hmg\/ddq460","volume":"20","author":"Maher P.","year":"2011","unstructured":"Maher P.; Dargusch R.; Bodai L.; Gerard P.E.; Purcell J.M.; Marsh J.L.; ERK activation by the polyphenols fisetin and resveratrol pro-vides neuroprotection in multiple models of Huntington\u2019s disease. Hum Mol Genet 2011,20(2),261-270","journal-title":"Hum Mol Genet"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"58","DOI":"10.2741\/S425","volume":"7","author":"Maher P.","year":"2015","unstructured":"Maher P.; Fisetin acts on multiple pathways to reduce the impact of age and disease on CNS function. Front Biosci (Schol Ed) 2015,7,58-82","journal-title":"Front Biosci (Schol Ed)"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"174492","DOI":"10.1016\/j.ejphar.2021.174492","volume":"910","author":"Ravula A.R.","year":"2021","unstructured":"Ravula A.R.; Teegala S.B.; Kalakotla S.; Pasangulapati J.P.; Perumal V.; Boyina H.K.; Fisetin, potential flavonoid with multifarious targets for treating neurological disorders: An updated review. Eur J Pharmacol 2021,910,174492","journal-title":"Eur J Pharmacol"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"18736","DOI":"10.1038\/srep18736","volume":"6","author":"Chongtham A.","year":"2016","unstructured":"Chongtham A.; Agrawal N.; Curcumin modulates cell death and is protective in Huntington\u2019s disease model. Sci Rep 2016,6(1),18736","journal-title":"Sci Rep"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.2174\/1570159X18666200522201123","volume":"19","author":"Labanca F.","year":"2021","unstructured":"Labanca F.; Ullah H.; Khan H.; Milella L.; Xiao J.; Dajic-Stevanovic Z.; Jeandet P.; Therapeutic and mechanistic effects of curcumin in Huntington\u2019s disease. Curr Neuropharmacol 2021,19(7),1007-1018","journal-title":"Curr Neuropharmacol"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.1093\/hmg\/ddz247","volume":"28","author":"Elifani F.","year":"2019","unstructured":"Elifani F.; Amico E.; Pepe G.; Capocci L.; Castaldo S.; Rosa P.; Montano E.; Pollice A.; Madonna M.; Filosa S.; Calogero A.; Maglio-ne V.; Crispi S.; Di Pardo A.; Curcumin dietary supplementation ameliorates disease phenotype in an animal model of Huntington\u2019s dis-ease. Hum Mol Genet 2019,28(23),4012-4021","journal-title":"Hum Mol Genet"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3390\/antiox9080706","volume":"9","author":"Imran M.","year":"2020","unstructured":"Imran M.; Ghorat F.; Ul-Haq I.; Ur-Rehman H.; Aslam F.; Heydari M.; Shariati M.A.; Okuskhanova E.; Yessimbekov Z.; Thiruvenga-dam M.; Hashempur M.H.; Rebezov M.; Lycopene as a natural antioxidant used to prevent human health disorders. Antioxidants 2020,9(8),706","journal-title":"Antioxidants"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.biopha.2018.12.151","volume":"111","author":"Chen D.","year":"2019","unstructured":"Chen D.; Huang C.; Chen Z.; A review for the pharmacological effect of lycopene in central nervous system disorders. Biomed Pharmacother 2019,111,791-801","journal-title":"Biomed Pharmacother"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2217\/nnm-2020-0239","volume":"16","author":"Cano A.","year":"2021","unstructured":"Cano A.; Ettcheto M.; Espina M.; Auladell C.; Folch J.; K\u00fchne B.A.; Barenys M.; S\u00e1nchez-L\u00f3pez E.; Souto E.B.; Garc\u00eda M.L.; Turowski P.; Camins A.; Epigallocatechin-3-gallate PEGylated poly(lactic-co-glycolic) acid nanoparticles mitigate striatal pathology and motor deficits in 3-nitropropionic acid intoxicated mice. Nanomedicine (Lond) 2021,16(1),19-35","journal-title":"Nanomedicine (Lond)"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"20309","DOI":"10.1021\/acsami.6b06853","volume":"8","author":"Debnath K.","year":"2016","unstructured":"Debnath K.; Shekhar S.; Kumar V.; Jana N.R.; Jana N.R.; Efficient inhibition of protein aggregation, disintegration of aggregates, and low-ering of cytotoxicity by green tea polyphenol-based self-assembled polymer nanoparticles. ACS Appl Mater Interfaces 2016,8(31),20309-20318","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1007\/s12035-021-02397-8","volume":"58","author":"Joshi T.","year":"2021","unstructured":"Joshi T.; Kumar V.; Kaznacheyeva E.V.; Jana N.R.; Withaferin A.; Withaferin a induces heat shock response and ameliorates disease progression in a mouse model of Huntington\u2019s disease. Mol Neurobiol 2021,58(8),3992-4006","journal-title":"Mol Neurobiol"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"186","DOI":"10.5455\/jice.20140903012921","volume":"3","author":"Jain D.","year":"2014","unstructured":"Jain D.; Gangshettiwar A.; Combination of lycopene, quercetin and poloxamer 188 alleviates anxiety and depression in 3-nitropropionic acid-induced Huntington\u2019s disease in rats. J Intercult Ethnopharmacol 2014,3(4),186-191","journal-title":"J Intercult Ethnopharmacol"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.neulet.2008.10.020","volume":"448","author":"Park J-E.","year":"2008","unstructured":"Park J-E.; Lee S-T.; Im, W.S.; Chu, K.; Kim, M. Galantamine reduces striatal degeneration in 3-nitropropionic acid model of Huntington\u2019s disease. Neurosci Lett 2008,448(1),143-147","journal-title":"Neurosci Lett"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/00004850-200401000-00010","volume":"19","author":"Petrikis P.","year":"2004","unstructured":"Petrikis P.; Andreou C.; Piachas A.; Bozikas V.P.; Karavatos A.; Treatment of Huntington\u2019s disease with galantamine. Int Clin Psychopharmacol 2004,19(1),49-50","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"153883","DOI":"10.1016\/j.phymed.2021.153883","volume":"95","author":"Chen Y-Y.","year":"2022","unstructured":"Chen Y-Y.; Liu Q-P.; An P.; Jia M.; Luan X.; Tang J-Y.; Zhang H.; Ginsenoside Rd: A promising natural neuroprotective agent. Phytomedicine 2022,95,153883","journal-title":"Phytomedicine"},{"key":"ref=169","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgr.2021.11.003","author":"Hua K-F.","year":"2021","unstructured":"Hua K-F.; Chao A-C.; Lin T-Y.; Chen W-T.; Lee Y-C.; Hsu W-H.; Lee S-L.; Wang H-M.; Yang D-I.; Ju T-C.; Ginsenoside compound K reduces the progression of Huntington\u2019s disease via the inhibition of oxidative stress and overactivation of the ATM\/AMPK pathway. J Ginseng Res 2021","journal-title":"J Ginseng Res"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s11626-021-00595-1","volume":"57","author":"Lee M.","year":"2021","unstructured":"Lee M.; Ban J-J.; Won B.H.; Im, W.; Kim, M. Therapeutic potential of ginsenoside Rg3 and Rf for Huntington\u2019s disease. In Vitro Cell Dev Biol Anim 2021,57(6),641-648","journal-title":"In Vitro Cell Dev Biol Anim"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1038\/s41401-020-00558-4","volume":"42","author":"Yang X.","year":"2021","unstructured":"Yang X.; Chu S.F.; Wang Z.Z.; Li F.F.; Yuan Y.H.; Chen N.H.; Ginsenoside Rg1 exerts neuroprotective effects in 3-nitropronpionic acid-induced mouse model of Huntington\u2019s disease via suppressing MAPKs and NF-","journal-title":"Acta Pharmacol Sin"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"112876","DOI":"10.1016\/j.jep.2020.112876","volume":"257","author":"Zahiruddin S.","year":"2020","unstructured":"Zahiruddin S.; Basist P.; Parveen A.; Parveen R.; Khan W.; Gaurav; Ahmad, S. Ashwagandha in brain disorders: A review of recent developments. J Ethnopharmacol 2020,257,112876","journal-title":"J Ethnopharmacol"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1007\/s11064-015-1658-2","volume":"40","author":"Singh S.","year":"2015","unstructured":"Singh S.; Jamwal S.; Kumar P.; Piperine enhances the protective effect of curcumin against 3-NP induced neurotoxicity: Possible neuro-transmitters modulation mechanism. Neurochem Res 2015,40(8),1758-1766","journal-title":"Neurochem Res"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4103\/0973-7847.120505","volume":"7","author":"Choudhary S.","year":"2013","unstructured":"Choudhary S.; Kumar P.; Malik J.; Plants and phytochemicals for Huntington\u2019s disease. Pharmacogn Rev 2013,7(14),81-91","journal-title":"Pharmacogn Rev"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.bbr.2009.08.028","volume":"206","author":"Kumar P.","year":"2010","unstructured":"Kumar P.; Kumar A.; Protective effect of hesperidin and naringin against 3-nitropropionic acid induced Huntington\u2019s like symptoms in rats: Possible role of nitric oxide. Behav Brain Res 2010,206(1),38-46","journal-title":"Behav Brain Res"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11010-015-2525-9","volume":"409","author":"Kulasekaran G.","year":"2015","unstructured":"Kulasekaran G.; Ganapasam S.; Neuroprotective efficacy of naringin on 3-nitropropionic acid-induced mitochondrial dysfunction through the modulation of Nrf2 signaling pathway in PC12 cells. Mol Cell Biochem 2015,409(1-2),199-211","journal-title":"Mol Cell Biochem"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.neuint.2011.08.022","volume":"59","author":"Gopinath K.","year":"2011","unstructured":"Gopinath K.; Prakash D.; Sudhandiran G.; Neuroprotective effect of naringin, a dietary flavonoid against 3-nitropropionic acid-induced neuronal apoptosis. Neurochem Int 2011,59(7),1066-1073","journal-title":"Neurochem Int"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.bbadis.2012.11.018","volume":"1832","author":"Sandhir R.","year":"2013","unstructured":"Sandhir R.; Mehrotra, A Quercetin supplementation is effective in improving mitochondrial dysfunctions induced by 3-nitropropionic acid: Implications in Huntington\u2019s disease. Biochim Biophys Acta BBA - Mol. Basis Dis 2013,1832,421-430","journal-title":"Basis Dis"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1016\/j.jns.2013.07.498","volume":"333","author":"Kuhad A.","year":"2013","unstructured":"Kuhad A.; Singla S.; Arora V.; Chopra K.; Neuroprotective effect of sesamol and quercetin against QA induced neurotoxicity: An experi-mental paradigm of Huntington\u2019s disease. J Neurol Sci 2013,333,e149-e150","journal-title":"J Neurol Sci"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"27933","DOI":"10.1021\/acsomega.0c03266","volume":"5","author":"Girme A.","year":"2020","unstructured":"Girme A.; Saste G.; Pawar S.; Balasubramaniam A.K.; Musande K.; Darji B.; Satti N.K.; Verma M.K.; Anand R.; Singh R.; Vish-wakarma R.A.; Hingorani L.; Investigating 11 withanosides and withanolides by UHPLC-PDA and mass fragmentation studies from Ashwagandha (Withania somnifera). ACS Omega 2020,5(43),27933-27943","journal-title":"ACS Omega"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1089\/jmf.2008.0028","volume":"12","author":"Kumar P.","year":"2009","unstructured":"Kumar P.; Kumar A.; Possible neuroprotective effect of Withania somnifera root extract against 3-nitropropionic acid-induced behavioral, biochemical, and mitochondrial dysfunction in an animal model of Huntington\u2019s disease. J Med Food 2009,12(3),591-600","journal-title":"J Med Food"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1093\/hmg\/ddl210","volume":"15","author":"Ehrnhoefer D.E.","year":"2006","unstructured":"Ehrnhoefer D.E.; Duennwald M.; Markovic P.; Wacker J.L.; Engemann S.; Roark M.; Legleiter J.; Marsh J.L.; Thompson L.M.; Lind-quist S.; Muchowski P.J.; Wanker E.E.; Green tea (-)-epigallocatechin-gallate modulates early events in Huntingtin misfolding and reduces toxicity in Huntington\u2019s disease models. Hum Mol Genet 2006,15(18),2743-2751","journal-title":"Hum Mol Genet"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.expneurol.2011.08.014","volume":"232","author":"Pasinetti G.M.","year":"2011","unstructured":"Pasinetti G.M.; Wang J.; Marambaud P.; Ferruzzi M.; Gregor P.; Knable L.A.; Ho L.; Neuroprotective and metabolic effects of resvera-trol: Therapeutic implications for Huntington\u2019s disease and other neurodegenerative disorders. Exp Neurol 2011,232(1),1-6","journal-title":"Exp Neurol"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"24126","DOI":"10.1021\/acsami.7b06510","volume":"9","author":"Debnath K.","year":"2017","unstructured":"Debnath K.; Pradhan N.; Singh B.K.; Jana N.R.; Jana N.R.; Poly(trehalose) nanoparticles prevent amyloid aggregation and suppress poly-glutamine aggregation in a Huntington\u2019s disease model mouse. ACS Appl Mater Interfaces 2017,9(28),24126-24139","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"e90202","DOI":"10.1371\/journal.pone.0090202","volume":"9","author":"Fernandez-Estevez M.A.","year":"2014","unstructured":"Fernandez-Estevez M.A.; Casarejos M.J.; L\u00f3pez Sendon J.; Garcia Caldentey J.; Ruiz C.; Gomez A.; Perucho J.; de Yebenes J.G.; Mena M.A.; Trehalose reverses cell malfunction in fibroblasts from normal and Huntington\u2019s disease patients caused by proteosome inhi-bition. PLoS One 2014,9(2),e90202","journal-title":"PLoS One"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1039\/C2MD20112G","volume":"4","author":"Im J.","year":"2013","unstructured":"Im J.; Kim S.; Jeong Y-H.; Kim W.; Lee D.; Lee W.S.; Chang Y-T.; Kim K-T.; Chung S-K.; Preparation and evaluation of BBB-permeable trehalose derivatives as potential therapeutic agents for Huntington\u2019s disease. MedChemComm 2013,4(2),310-316","journal-title":"MedChemComm"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/nm985","volume":"10","author":"Tanaka M.","year":"2004","unstructured":"Tanaka M.; Machida Y.; Niu S.; Ikeda T.; Jana N.R.; Doi H.; Kurosawa M.; Nekooki M.; Nukina N.; Trehalose alleviates polygluta-mine-mediated pathology in a mouse model of Huntington disease. Nat Med 2004,10(2),148-154","journal-title":"Nat Med"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"16037","DOI":"10.1038\/mtm.2016.37","volume":"3","author":"Hadaczek P.","year":"2016","unstructured":"Hadaczek P.; Stanek L.; Ciesielska A.; Sudhakar V.; Samaranch L.; Pivirotto P.; Bringas J.; O\u2019Riordan C.; Mastis B.; San Sebastian W.; Forsayeth J.; Cheng S.H.; Bankiewicz K.S.; Shihabuddin L.S.; Widespread AAV1- and AAV2-mediated transgene expression in the nonhuman primate brain: Implications for Huntington\u2019s disease. Mol Ther Methods Clin Dev 2016,3,16037","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.omtn.2017.04.011","volume":"7","author":"Pfister E.L.","year":"2017","unstructured":"Pfister E.L.; Chase K.O.; Sun H.; Kennington L.A.; Conroy F.; Johnson E.; Miller R.; Borel F.; Aronin N.; Mueller C.; Safe and effi-cient silencing with a Pol II, but Not a Pol lII, promoter expressing an artificial miRNA targeting human Huntingtin. Mol Ther Nucleic Acids 2017,7,324-334","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/mt.2013.289","volume":"22","author":"Dufour B.D.","year":"2014","unstructured":"Dufour B.D.; Smith C.A.; Clark R.L.; Walker T.R.; McBride J.L.; Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in Huntington\u2019s disease mice. Mol Ther 2014,22(4),797-810","journal-title":"Mol Ther"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","volume":"380","author":"Tabrizi S.J.","year":"2019","unstructured":"Tabrizi S.J.; Leavitt B.R.; Landwehrmeyer G.B.; Wild E.J.; Saft C.; Barker R.A.; Blair N.F.; Craufurd D.; Priller J.; Rickards H.; Rosser A.; Kordasiewicz H.B.; Czech C.; Swayze E.E.; Norris D.A.; Baumann T.; Gerlach I.; Schobel S.A.; Paz E.; Smith A.V.; Ben-nett C.F.; Lane R.M.; Targeting Huntingtin expression in patients with Huntington\u2019s disease. N Engl J Med 2019,380(24),2307-2316","journal-title":"N Engl J Med"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/stem.2747","volume":"36","author":"Connor B.","year":"2018","unstructured":"Connor B.; Concise review: The use of stem cells for understanding and treating Huntington\u2019s disease. Stem Cells 2018,36(2),146-160","journal-title":"Stem Cells"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/sctm.19-0248","volume":"9","author":"Srinageshwar B.","year":"2020","unstructured":"Srinageshwar B.; Petersen R.B.; Dunbar G.L.; Rossignol J.; Prion-like mechanisms in neurodegenerative disease: Implications for Hun-tington\u2019s disease therapy. Stem Cells Transl Med 2020,9(5),559-566","journal-title":"Stem Cells Transl Med"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/mt.2016.12","volume":"24","author":"Pollock K.","year":"2016","unstructured":"Pollock K.; Dahlenburg H.; Nelson H.; Fink K.D.; Cary W.; Hendrix K.; Annett G.; Torrest A.; Deng P.; Gutierrez J.; Nacey C.; Pep-per K.; Kalomoiris S.D.; Anderson J.; McGee J.; Gruenloh W.; Fury B.; Bauer G.; Duffy A.; Tempkin T.; Wheelock V.; Nolta J.A.; Human mesenchymal stem cells genetically engineered to overexpress brain-derived neurotrophic factor improve outcomes in Huntington\u2019s disease mouse models. Mol Ther 2016,24(5),965-977","journal-title":"Mol Ther"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1111\/ejn.13275","volume":"44","author":"Lee M.","year":"2016","unstructured":"Lee M.; Liu T.; Im W.; Kim M.; Exosomes from adipose-derived stem cells ameliorate phenotype of Huntington\u2019s disease in vitro model. Eur J Neurosci 2016,44(4),2114-2119","journal-title":"Eur J Neurosci"}],"container-title":["Current Drug Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389200223666220321103942","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/202446\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389200223666220321103942","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T04:43:55Z","timestamp":1700369035000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/202446\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":195,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389200223666220321103942","relation":{},"ISSN":["1389-2002"],"issn-type":[{"value":"1389-2002","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-11-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}